Editorial: Retreatment of direct-acting antiviral failures with the current first-line regimens for patients with chronic hepatitis C

Affiliations

Editorial

Eiichi Ogawa. Aliment Pharmacol Ther. 2024 Jul.

. 2024 Jul;60(2):276-277.

doi: 10.1111/apt.18041. Epub 2024 Jun 16.

¹ Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.

No abstract available

Comment on

Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, Diago M, García-Samaniego J, Castellote J, Llerena S, Rodríguez-Seguel E, Mateos B, Rodríguez M, Rosales Zabal JM, Fernández I, Calleja JL, Morillas RM, Montoliu S, Andrade RJ, Badia Aranda E, Hernández-Guerra M, Maté CJ, González-Santiago JM, de Cuenca B, Bernal-Monterde V, Delgado M, Turnes J, Lens S, Buti M. Ruiz-Cobo JC, et al. Aliment Pharmacol Ther. 2024 Jul;60(2):201-211. doi: 10.1111/apt.18020. Epub 2024 May 2. Aliment Pharmacol Ther. 2024. PMID: 38695095

1. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–1218.
1. Bhattacharya D, Aronsohn A, Price J, Lo Re V, AASLD‐IDSA HCV Guidance Panel. Hepatitis C Guidance. Update: AASLD‐IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023;2023. https://doi.org/10.1093/cid/ciad319
1. Graf C, D'Ambrosio R, Degasperi E, et al. Real‐world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. JHEP Rep. 2024;6:100994.
1. Ruiz‐Cobo JC, Llaneras J, Forns X, et al. Real‐life effectiveness of sofosbuvir/velpatasvir/voxilapreivr in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Aliment Pharmacol Ther. 2024;60:201–211.
1. Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben‐Ari Z, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus‐infected patients with end‐stage renal disease undergoing dialysis. J Hepatol. 2019;71:660–665.